SIP Bioreactor Market Report: Trends, Forecast and Competitive Analysis to 2035

SIP Bioreactor Market

The future of the global sip bioreactor market looks promising with opportunities in the biopharmaceutical and scientific research markets. The global sip bioreactor market is expected to reach an estimated $1.7 billion by 2035 from $1.1 billion in 2027 with a CAGR of 6.8% from 2027 to 2035. The major drivers for this market are the increasing demand for contamination free bioprocessing, the rising adoption of single use bioreactors, and the growing investment in biopharmaceutical manufacturing technologies.

• Lucintel forecasts that, within the type category, single-use is expected to witness higher growth over the forecast period due to more single-use systems promote cost savings and lower contamination risk.
• Within the application category, biopharmaceutical is expected to witness higher growth over the forecast period due to the biopharmaceutical industry is developing and growing rapidly.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the investment and infrastructure for biomanufacturing are also increasing.

Emerging Trends in SIP Bioreactor Market

The sip bioreactor market is changing from use in research to commercial, large scale bioprocessing. Between 2025 and 2027, market trends are expected to include increased regulation and the large-scale adoption of single-use bioprocessing. Lucintel predicts suppliers of sip bioreactor systems will focus on larger vessels and automated systems.

• Single-use Systems: The commercial availability of larger single-use bioreactor systems (up to 2,000 L) in 2025 reduced the need for large-scale facilities to perform clearing validation. This improved the flexibility and reduced the costs associated with changing the process to manufacture different biological drugs.
• Process Intensification: The use of perfusion and other high-cell density bioprocesses continued to increase in 2025, particularly in the development of therapeutic antibodies, to improve volumetric productivity and decrease the time required for bioprocessing.
• Digital and Automated Processes: The use of real-time process analytical technology and other process control systems to automate bioprocessing continued in 2025, with a focus on reducing variability and improving consistency.
• Therapeutic Diversification: Between 2025-2027, cell and gene therapy and monoclonal antibody developers will increase small-scale commercial manufacturing. During this time, sponsor organizations will increase their technology and supplier base. sipp bioreactors will be better positioned due to their flexibility to rapidly change media and short-term campaigns.
• Supply Chain Resiliency: Biologics capacity additions in North America, Europe and Asia will allow customers to evaluate multiple suppliers and source materials. The 2025-2027 contracts will favor suppliers that have redundant manufacturing sites.

Between 2025 and 2027, sip bioreactor systems will be better positioned due to process flexibility, rapid technology and media changes, and manufacturing campaign integrations with downstream processes.

Recent Developments in the SIP Bioreactor Market

The sip bioreactor market is expected to grow over the next few years as the biologics pipeline expands and biomanufacturers focus on more flexible closed processing systems. During this period, Lucintel expects that the sip bioreactor market will gain momentum due to increasing automation and intensity in biologics upstream processing, as well as investments to build biopharmaceutical manufacturing capacity. As the biopharmaceutical market grows, sponsors and end-users are concerned about the total cost of ownership of biologics and the validation of the supply chain.

• Capacity Addition: In February 2025, Thermo Fisher Scientific announced a $2 billion expansion of its bioprocess single-use manufacturing operations in the United States.
• Collaboration: Repligen and Sartorius also announced in January 2025 an expansion of their collaboration to integrate single-use and related systems and services.
• Cytiva's Bioreactor: Cytiva released their higher-productivity bioreactors in 2025, with enhanced process controls and on-line monitoring. Other bioreactor manufacturers should consider fully integrating process controls and leveraging connected services to better meet customers' process control needs, which could result in a competitive edge.
• Merck's Expansion: Merck Group's bioprocessing service and facility expansion in 2025, particularly in Asia, not only enhanced Merck Group's process and supply-chain resilience, but also developed local manufacturing capabilities and offered local process options to biologics clients.
• Fujifilm's Expansion: Fujifilm Diosynth Biotechnologies' (FDB) expansion of large-scale mammalian cell culture in the U.S. in 2025 created additional contract manufacturing capacity. FDB's and other contract manufacturers' increased capacity is likely to increase the development and use of single-use bioreactors. Other supply chain improvements may also increase the use of sip bioreactors

Strategic Growth Opportunities in the SIP Bioreactor Market

According to Lucintel, demand will continue to grow in the bioreactor market beyond 2026. Traditionally, the bioreactor market was mainly focused on the production of monoclonal antibodies. However, the market is expanding due to the increased adoption of cell and gene therapies and other rising trends in the biopharmaceutical market. From Lucintel's viewpoint, biopharmaceutical companies that focus on manufacturing processes will have a competitive edge in the market.

• Cell and Gene Therapy Manufacturing: Biopharmaceutical manufacturers utilize SIP bioreactors to manufacture viral vectors and expand cells. It is anticipated that the demand for cell and gene therapies will increase with the FDA's approval of more commercial manufacturing of these therapies.
• Processing: The use of SIP systems for seed train and other long duration continuous processes, and other intensified biopharmaceutical manufacturing strategies, will increase in the industry.
• Biopharmaceutical Manufacturing in New Geographic Locations: The 2025 budget of India's Department of Pharmaceuticals, which allocated ₹1,000 crore to enhance biopharmaceutical and pharmaceutical research and development, will stimulate the adoption and use of validated SIP (Single-Use Process) technologies and other biopharmaceutical manufacturing processes.
• Single-use Systems: Consumers expect lower use of plastic while still requiring a high level of sterility in products and processes. In February 2025, Sartorius announced sustainability targets to reduce operational emissions by 30% by 2030. Clients will reward the biggest weight reduction of single-use films and best recyclability in the next five years.
• Digital Process Integration: Sensors and data analysis, when combined with SIP bioreactors, help address batch variability and accelerate process technology transfer. In April 2025, the ISPE Pharma 4.0 community identified data integrity as a key manufacturing objective. Further development of digital functionalities will increase competition for bioreactors to other integrated and validated software and process solutions.

Incorporating additional process steps and equipment with SIP bioreactors creates a more integrated and continuous production process. The best-in-class positions will be created through application and process development. Consumables and equipment will be rewarded for batch integrity and reduction of process changeover. Protecting batch integrity and reducing changeover will be more economically valuable than price reduction.

SIP Bioreactor Market Drivers and Challenges

The sip bioreactor market is a result of the influence of various trends like technology, economy, and other market environment factors. Lucintel anticipates that increasing adoption of sip bioreactors will be a result of the necessity for flexible biomanufacturing and faster development of complex biologics. Challenges to adoption will include high costs, and lack of sufficient and reliable supply of autonomous and skilled personnel to operate bioreactor equipment. Automation and single-use systems will gain preference in bioprocessing. Therefore, in the future, companies will need to focus on synchronizing process and product in order to ensure the integration of flexibility, sustainability and continuous improvement in their products and services.

The factors responsible for driving this market include :

• Rising Biologics: In 2025, over 40% of the global pharmaceutical pipeline was comprised of biologics. Continued investments in flexible manufacturing of biologics has led to an increasing number of biologics in the pipeline. Pharmaceutical and biotechnology companies will need sip bioreactors to manufacture biologics for the pipeline and commercial purposed in the coming years.
• Trends in Technology: Improved automation, analytics, sensors, and other process controls will permit even greater control and consistency in bioreactor operations. In 2025, the majority of bioreactor systems employed real-time monitoring of at least four critical process controls. These process controls included pH, dissolved oxygen, temperature, and agitation. These features allowed for greater process control and consistency among bioreactor operations. Additionally, in the next 3-5 years, process control and automation systems would further integrate and allow for process optimization and predictive maintenance.
• Increased Use of Single-Use Systems: Single-use systems provide benefits such as reduced time and effort required for system changeover and cross-contamination. In 2025, single-use systems ranging in size from 50L to 2000L were used in several biomanufacturing facilities. In the next 3-5 years, single-use systems would gain broader use due to improved flexibility in manufacturing when compared with traditional systems.
• Variable Demand: The biomanufacturing industry utilizes sip bioreactors in conjunction with other equipment to gain the ability to quickly and easily change their production based on varying customer demand. During this time, equipment was modified in days as opposed to months to enable the manufacturing of different biological drugs. Sip bioreactors would further benefit manufacturing by enabling production of a varied and unpredictable product portfolio.
• Manufacturing Efficiency and Cost Reduction: Better impeller designs, automated feeding systems, and improved oxygen transfer, coupled with standardized, disposable bioprocessing elements, can increase productivity and decrease labor and turnaround times. Some 2025 bioprocessing systems focused on reducing batch-change times, with many achieving times in excess of 90% reduction. Continuous improvements in bioprocessing systems are expected in the next 3-5 years, particularly systems integrating more automation and control.

The challenges facing this market include:

• Capital Investment: The automation and disposable nature of sip bioreactors increases the upfront cost of bioprocessing systems. In 2025, fully integrated, flexible, automated bioprocessing systems were estimated to cost more than $500,000. This high initial cost of investment may deter research and biotechnology companies from adopting the latest bioprocessing technologies. The same financial constraints may promote modular, leased, or contracted bioprocessing systems in the 2025-2030 time frame.
• Regulatory and Validation Challenges: Stringent regulations for the biopharmaceutical industry increase the cost and extend the time required for bioprocessing system validation. The presence of multiple quality attributes in disposable bioprocessing components increases the duration and costs of qualification. About 20 quality attributes were typically assessed during the qualification of disposable bioprocessing components in 2025. In the 2025-2030 time frame, the same regulatory hurdles may largely affect the bioprocessing of advanced therapy products, while progress in validation and supplier assurance may mitigate hurdles for other products.
• Supply-Chain Concerns: Reliance on specialized disposable components, e.g. films, sensors, tubing and filters, increases risk of disruptions in manufacturing. In 2026, one process may involve use of over 200 disposable components. This increases supply-chain complexity and waste management issues. In the near-future, to reduce the effects of waste and increase sustainability of products, there will be a focus on reduction of disposable components and process optimization. It may also lead to increased costs for manufacturers due to more stringent regulation concerning waste disposal

There are a number of sustainability risks associated with the current single-use bioreactor platforms. Many of the platforms rely on the use of single-use consumables. Disruptive events in the supply chain can effect price, availability and continuity of supply of these consumables. In 2026, a particular bioprocess may require 200 or more single use components increasing complexity of supply and raising waste management concerns. During the next three to five years, the biopharmaceutical industry is expected to implement lower-waste processes and material sourcing. Other sustainability initiatives may increase the cost and complexity of doing business. This will require biopharmaceutical companies to find a balance between sustainability and cost.

The sip bioreactor market is expected to grow due to many of the same trends affecting the overall biologics market. The sip bioreactor market will also benefit from the need for flexible and automated processes. Single-use bioreactors create process consistency and reduce facility changeover times. Disposable components increase operational risk and raise concerns about the long-term viability of the platform. There will be a growing focus on lower-waste processes and more sustainable systems. The use of single-use bioreactors may raise ethical concerns about sustainability. In the short-term, single-use bioreactors will continue to benefit from relaxed regulation.

List of SIP Bioreactor Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies sip bioreactor market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the sip bioreactor market companies profiled in this report include-

• Cytiva
• Merck
• Sartorius
• Getinge
• Corning

SIP Bioreactor Market by Segment

The study includes a forecast for the global sip bioreactor market by type, application, and region.

SIP Bioreactor Market by Type [Value ($B) from 2019 to 2035]:

• Long-Lasting
• Single-Use

SIP Bioreactor Market by Application [Value ($B) from 2019 to 2035]:

• Biopharmaceutical
• Scientific Research
• Others

SIP Bioreactor Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the SIP Bioreactor Market

Major biopharmaceutical companies are increasing the number of sterilize-in-place (SIP) capacity bioreactors and supporting closed, automated biopharmaceutical manufacturing. Over the next few years, significant projects in facility construction and expansion and update of modular and automated equipment are anticipated. Lucintel expects these projects to increase the need for SIP system validation.

• United States: One of the major companies in the U.S., Thermo Fisher Scientific, announced a $650 million expansion of its biologics manufacturing facility in Plainville, Massachusetts (June 2021). Thermo Fisher is expected to increase its domestic automated SIP bioreactor capacity and integrated systems for cleaning validation over the next decade.
• China: In December 2021, WuXi Biologics announced the large-scale drug substance manufacturing facility at its Chinese campus. The SIP bioreactor capacity is 36,000 liters. The project, along with similar initiatives in China, is expected to drive the country's biologics manufacturing policy and the adoption of pre-fabricated integrated SIP systems over the next 3 to 5 years.
• Germany: Sartorius received approval for a €100 million investment to build additional manufacturing facilities at their Guxhagen campus in 2024. By 2025, they will further invest to build additional facilities to manufacture bioreactor hardware and other single-use systems. These systems will be manufactured using Sartorius Integrated Product (SIP) technology and provided for commercial production.
• India: The Biomanufacturing policy (BioE3) passed by the Department of Biotechnology in August 2024 will drive the development of biomanufacturing facilities and pilot plants across India. Additionally, Biocon Biologics will build more manufacturing facilities in Bengaluru. As more biologics move from the development to commercial production phase in India, SIP bioreactors will be installed in these facilities.
• Japan: Fujifilm's collaboration with the National Institute of Infectious Diseases of Japan (2025) to build a vaccine manufacturing facility under Japan's Advanced Vaccine Initiative will help accelerate the use of single-use modular bioreactors and other automated systems for Sterile Fill and Finish in Japan.

Features of the Global SIP Bioreactor Market

• Market Size Estimates: sip bioreactor market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: sip bioreactor market size by type, application, and region in terms of value ($B).
• Regional Analysis: sip bioreactor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the sip bioreactor market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the sip bioreactor market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the sip bioreactor market by type (long-lasting and single-use), application (biopharmaceutical, scientific research, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?